Prognostics

Tumors with High PTA Levels Related to Poor Outcome

Published in Breast Cancer Weekly, April 8th, 2000

Scientists say that breast cancer patients with tumors having high prothymosin alpha (PTA) levels can expect a worse outcome than their counterparts with low or moderate PTA levels.

After having suggested in a previous study that PTA levels in primary breast tumors be used to identify patients at high risk for distant metastasis, C. Magdalena and colleagues designed another study to examine the role of PTA levels in relation to disease-free survival (DFS) and survival. Their findings were published in British Journal of Cancer ("Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer," Br J Cancer,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Breast Cancer Weekly

Source: Breast Cancer Weekly (2000-04-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry